FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. What is described is using specific conjugate molecules, which are cargo molecule transporters for transporting a substance of interest into leukocytes. There are described a method for producing the above conjugate molecules, which are the cargo molecule transporters, a method for transporting the substance of interest into leukocytes, and the leukocytes containing the above conjugate molecules, which are the cargo molecule transporters. The invention can be used in medicine.
EFFECT: above conjugate molecules, which are the cargo molecule transporters, can be used for treating, preventing, relieving and/or reducing the intensity of a disease and/or a disorder involving leukocytes.
26 cl, 34 dwg, 5 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL CONSTRUCTIONS OF TRANSPORTERS AND CONJUGATE MOLUCELES WHICH ARE TRASPORTERS OF CARGO-MOLECULES | 2009 |
|
RU2570632C2 |
| NOVEL MOLECULE INHIBITORS OF JNK | 2011 |
|
RU2570417C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
| METHODS AND COMPOSITION FOR INHIBITION OF HIV-1 MULTIPLICATION | 2001 |
|
RU2275379C2 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
| METASTIN DERIVATIVES AND APPLICATION THEREOF | 2006 |
|
RU2430107C2 |
| PEPTIDES HAVING AGONISTIC ACTIVITY ON NEUROPEPTIDE-2 RECEPTOR (Y2R) | 2006 |
|
RU2383553C2 |
| ANALOGUES OF GHRELIN SUBSTITUTED AT N-END | 2007 |
|
RU2459831C2 |
